Table 1.
Patient and Tumor Characteristics
| Characteristic | Anti PD-1 Naïve n (%) |
Anti PD-1 Experienced n (%) |
p |
|---|---|---|---|
| Patients | 112 | 69 | |
| Sex | 0.88 | ||
| Female | 42 (38) | 25 (36) | |
| Male | 70 (62) | 44 (64) | |
| Age, years | |||
| Median | 47 | 46 | 0.33 |
| 18–30 | 14 (12) | 9 (13) | 0.53 |
| 31–45 | 31 (28) | 24 (35) | |
| 46–60 | 62 (55) | 21 (30) | |
| 61–75 | 5 (5) | 15 (22) | |
| Stage, AJCC 8th Edition | 0.87 | ||
| M1a | 20 (18) | 15 (22) | |
| M1b | 25 (22) | 10 (14) | |
| M1c | 49 (44) | 35 (51) | |
| M1d | 18 (16) | 9 (13) | |
| Primary Site of Disease* | 0.81 | ||
| Head/Neck | 23 (21) | 13 (19) | |
| Trunk | 33 (29) | 26 (38) | |
| Extremity | 34 (30) | 17 (25) | |
| Acral | 8 (7) | 6 (9) | |
| Unknown | 14 (12) | 8 (12) | |
| Prior Systemic Therapy | |||
| Anti CTLA-4 | 35 (31) | 64 (93) | <0.0001 |
| Anti BRAF/MEK§ | 7 (13) | 20 (71) | <0.0001 |
| HD IL-2 | 35 (31) | 20 (43) | 0.87 |
| IFN-α | 34 (30) | 24 (35) | 0.62 |
| Chemotherapy | 16 (14) | 15 (13) | 0.22 |
| Other | 21 (19) | 23 (33) | 0.03 |
| BRAF V600 Status‡ | 0.54 | ||
| Mutated | 55 (49) | 30 (43) | |
| Wild Type | 57 (51) | 38 (55) | |
| Year of TIL Treatment† | <0.0001 | ||
| 2011–2014 | 98 (95) | 13 (28) | |
| 2015–2018 | 5 (5) | 34 (72) |
*
Single patient in anti PD-1 experienced group with two categorically different primaries
§
Percentages shown out of patients with melanoma harboring BRAF mutations
‡
Single patient without available tumor DNA for sequencing
†
Percentages shown out of patients who were treated with TIL